Devoted to the Pursuit of Clinical Excellence in Gastroenterology and Hepatology for Over 30 Years
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.
